A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

NCT07392892 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

840

Enrollment

INDUSTRY

Sponsor class

Conditions

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma
Metastatic Gastric Cancer
Gastroesophageal Junction Cancer
Esophageal Adenocarcinoma

Interventions

BIOLOGICAL: PF-08634404
DRUG: Chemotherapy
BIOLOGICAL: Nivolumab

Sponsor

Pfizer